RAR and RXR modulation in cancer and metabolic disease. - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue dressNature Reviews Drug Discovery Année : 2007

RAR and RXR modulation in cancer and metabolic disease.

Lucia Altucci
  • Fonction : Auteur
Mark D Leibowitz
  • Fonction : Auteur
Kathleen M Ogilvie
  • Fonction : Auteur
Angel R de Lera
  • Fonction : Auteur

Résumé

Retinoic acid receptors (RARs) are ligand-controlled transcription factors that function as heterodimers with retinoid X receptors (RXRs) to regulate cell growth and survival. The success of RAR modulation in the treatment of acute promyelocytic leukaemia (APL) has stimulated considerable interest in the development of RAR and RXR modulators. This has been aided by recent advances in the understanding of the biological role of RARs and RXRs and in the design of selective receptor modulators that might overcome the limitations of current drugs. Here, we discuss the challenges and opportunities for therapeutic strategies based on RXR and RAR modulators, with a focus on cancer and metabolic diseases such as diabetes and obesity.

Dates et versions

hal-00192059 , version 1 (26-11-2007)

Identifiants

Citer

Lucia Altucci, Mark D Leibowitz, Kathleen M Ogilvie, Angel R de Lera, Hinrich Gronemeyer. RAR and RXR modulation in cancer and metabolic disease.. dressNature Reviews Drug Discovery, 2007, 6 (10), pp.793-810. ⟨10.1038/nrd2397⟩. ⟨hal-00192059⟩
49 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More